{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:13:26Z","timestamp":1787026406094,"version":"build-2736575974"},"reference-count":124,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Glucose-dependent insulinotropic polypeptide (GIP) is an intestinal hormone that potentiates glucose-induced insulin secretion in the postprandial state. GIP exerts a broad range of other physiological actions e.g. in the pancreas, bone tissue, and vasculature. In more than 20 years, GIP receptor antagonism has contributed to the discoveries of the role of GIP within both human and animal physiology. In 1986, a fragment of the biological active bovine GIP(1-42), was discovered and characterized as the first GIP receptor antagonist. Several different molecules have been identified, including peptides, vaccines against GIP, GIP antibodies, and antibodies against the GIP receptor. Today, GIP receptor antagonists are not only used as scientific tools but due to significant metabolic effects, they also have a therapeutic purpose. The beneficial clinical effects of GIP receptor antagonism are supported by comparable phenotypic traits of individuals with loss-of-function genetic receptor variants. Novel insights into GIP receptor targeting treatment reveal that both GIP receptor antagonists and agonists, when combined with glucagon like peptide 1 (GLP-1) receptor activation, are associated with improved glycemic control and weight loss. This paradoxical scenario highlights the complexity of GIP receptor pharmacology. Moreover, the long-term effects of therapeutic GIP receptor antagonism in humans are not fully elucidated and are thought to depend on the specific drug molecule, receptor functions, and the extent of GLP-1 receptor activation. With this review, we provide an overview of the preclinical and clinical evidence of GIP receptor antagonism from the central early findings to the current therapeutics in clinical development. Finally, the current therapeutic developments and the further therapeutic potential within GIP receptor antagonism are discussed.<\/jats:p>","DOI":"10.3389\/fendo.2025.1570603","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:14:20Z","timestamp":1747786460000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["The evolution of the therapeutic concept \u2018GIP receptor antagonism\u2019"],"prefix":"10.3389","volume":"16","author":[{"given":"Frederikke","family":"Koefoed-Hansen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads Marstrand","family":"Helsted","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00fcs\u00fcn Sheyma","family":"Kizilkaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asger Bach","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette Marie","family":"Rosenkilde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e6rke Smidt","family":"Gasbjerg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/BF00492251","article-title":"Electronimmunocytochemical evidence for the K cell localization of gastric inhibitory polypeptide (GIP) im man","volume":"56","author":"Buchan","year":"1978","journal-title":"Histochemistry"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-017-4450-9","article-title":"Enteroendocrine K and L cells in healthy and type 2 diabetic individuals","volume":"61","author":"Jorsal","year":"2018","journal-title":"Diabetologia"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqab065","article-title":"The role of incretins on insulin function and glucose homeostasis","volume":"162","author":"Holst","year":"2021","journal-title":"Endocrinology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12902-024-01566-9","article-title":"Secretion of glucagon, GLP-1 and GIP may be affected by circadian rhythm in healthy males","volume":"24","author":"Zilstorff","year":"2024","journal-title":"BMC Endocrine Disord"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.2000.278.2.R360","article-title":"Effects of intraduodenal glucose and fructose on antropyloric motility and appetite in healthy humans","volume":"278","author":"Rayner","year":"2000","journal-title":"Am J Physiology-Regulatory Integr Comp Physiol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.90233.2008","article-title":"Incretin and islet hormonal responses to fat and protein ingestion in healthy men","volume":"295","author":"Carr","year":"2008","journal-title":"Am J Physiology-Endocrinology Metab"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-0266","article-title":"Incretin hormone and insulin responses to oral versus intravenous lipid administration in humans","volume":"96","author":"Lindgren","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-3865","article-title":"Incretin effect after oral amino acid ingestion in humans","volume":"100","author":"Lindgren","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1055\/s-2004-826160","article-title":"Circulation and degradation of GIP and GLP-1","volume":"36","author":"Deacon","year":"2005","journal-title":"Hormone Metab Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.85.10.6855","article-title":"Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide1","volume":"85","author":"Deacon","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12445","article-title":"Alternative form of glucose-dependent insulinotropic polypepide and its physiology","volume":"7","author":"Fujita","year":"2016","journal-title":"J Diabetes Invest"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.14469","article-title":"Establishment of novel specific assay for short-form glucose-dependent insulinotropic polypeptide and evaluation of its secretion in nondiabetic subjects","volume":"8","author":"Takeda","year":"2020","journal-title":"Physiol Rep"},{"key":"B13","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1093\/ejendo\/lvac015","article-title":"The naturally occurring GIP(1-30)NH2 is a GIP receptor agonist in humans","volume":"188","author":"Krogh","year":"2023","journal-title":"Eur J Endocrinol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13384","article-title":"N-terminally and C-terminally truncated forms of glucose-dependent insulinotropic polypeptide are high-affinity competitive antagonists of the human GIP receptor","volume":"173","author":"Hansen","year":"2016","journal-title":"Br J Pharmacol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1210\/endo.133.6.8243312","article-title":"Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain","volume":"133","author":"Usdin","year":"1993","journal-title":"Endocrinology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.2337\/db18-1123","article-title":"Separate and combined glucometabolic effects of endogenous glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 in healthy individuals","volume":"68","author":"Gasbjerg","year":"2019","journal-title":"Diabetes"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2337\/db11-0979","article-title":"Glucose-dependent insulinotropic polypeptide","volume":"60","author":"Christensen","year":"2011","journal-title":"Diabetes"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1210\/endo-123-4-2009","article-title":"Effect of truncated glucagon-like peptide-1 [Proglucagon-(78\u2013107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach","volume":"123","author":"\u00d8rskov","year":"1988","journal-title":"Endocrinology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2337\/db11-1451","article-title":"Xenin-25 amplifies GIP-mediated insulin secretion in humans with normal and impaired glucose tolerance but not type 2 diabetes","volume":"61","author":"Wice","year":"2012","journal-title":"Diabetes"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2019.05.014","article-title":"GLP-2 and GIP exert separate effects on bone turnover: A randomized, placebo-controlled, crossover study in healthy young men","volume":"125","author":"Skov-Jeppesen","year":"2019","journal-title":"Bone"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2013.73","article-title":"Glucose-dependent insulinotropic polypeptide has impaired effect on abdominal, subcutaneous adipose tissue metabolism in obese subjects","volume":"38","author":"Asmar","year":"2014","journal-title":"Int J Obes"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2337\/db17-0480","article-title":"The gluco- and liporegulatory and vasodilatory effects of glucose-dependent insulinotropic polypeptide (GIP) are abolished by an antagonist of the human GIP receptor","volume":"66","author":"Asmar","year":"2017","journal-title":"Diabetes"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1530\/EC-17-0015","article-title":"Effects of meal and incretins in the regulation of splanchnic blood flow","volume":"6","author":"Koffert","year":"2017","journal-title":"Endocrine Connections"},{"key":"B24","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1007\/s00125-023-05969-6","article-title":"The gut hormone GIP contributes to the postprandial gastrointestinal hyperaemia in humans","volume":"66","author":"Gasbjerg","year":"2023","journal-title":"Diabetologia"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2547","article-title":"Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans","volume":"99","author":"Nissen","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bone.2020.115553","article-title":"The role of endogenous GIP and GLP-1 in postprandial bone homeostasis","volume":"140","author":"Helsted","year":"2020","journal-title":"Bone"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/ejendo\/lvac004","article-title":"GIP reduces osteoclast activity and improves osteoblast survival in primary human bone cells","volume":"188","author":"Hansen","year":"2023","journal-title":"Eur J Endocrinol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-01949","article-title":"Glucose-dependent insulinotropic polypeptide (GIP) inhibits bone resorption independently of insulin and glycemia","volume":"103","author":"Christensen","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2019-00008","article-title":"Separate and combined effects of GIP and GLP-1 infusions on bone metabolism in overweight men without diabetes","volume":"104","author":"Bergmann","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B30","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.bcp.2018.01.040","article-title":"Human GIP(3-30)NH2 inhibits G protein-dependent as well as G protein-independent signaling and is selective for the GIP receptor with high-affinity binding to primate but not rodent GIP receptors","volume":"150","author":"Gabe","year":"2018","journal-title":"Biochem Pharmacol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.2337\/db21-1166","article-title":"GIPR is predominantly localized to nonadipocyte cell types within white adipose tissue","volume":"71","author":"Campbell","year":"2022","journal-title":"Diabetes"},{"key":"B32","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.cmet.2024.11.003","article-title":"The GIP receptor activates futile calcium cycling in white adipose tissue to increase energy expenditure and drive weight loss in mice","volume":"37","author":"Yu","year":"2025","journal-title":"Cell Metab"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2008.148","article-title":"Functional expression of glucose-dependent insulinotropic polypeptide receptors is coupled to differentiation in a human adipocyte model","volume":"32","author":"Weaver","year":"2008","journal-title":"Int J Obes"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2024.06.012","article-title":"Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor","volume":"36","author":"Regmi","year":"2024","journal-title":"Cell Metab"},{"key":"B35","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S0014-5793(02)02775-8","article-title":"Identification of G protein-coupled receptor genes from the human genome sequence","volume":"520","author":"Takeda","year":"2002","journal-title":"FEBS Lett"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2019.170224","article-title":"Molecular interactions of full-length and truncated GIP peptides with the GIP receptor \u2013 A comprehensive review","volume":"125","author":"Gabe","year":"2020","journal-title":"Peptides"},{"key":"B37","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/j.2040-1124.2012.00196.x","article-title":"Glucose-dependent insulinotropic polypeptide signaling in pancreatic \u03b2-cells and adipocytes","volume":"3","author":"McIntosh","year":"2012","journal-title":"J Diabetes Invest"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2023.119584","article-title":"Characterization of the real-time internalization of nine GPCRs reveals distinct dependence on arrestins and G proteins","volume":"1871","author":"M\u00f8ller","year":"2024","journal-title":"Biochim Biophys Acta (BBA) - Mol Cell Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-024-01061-4","article-title":"Characterization of genetic variants of GIPR reveals a contribution of \u03b2-arrestin to metabolic phenotypes","volume":"6","author":"Kizilkaya","year":"2024","journal-title":"Nat Metab"},{"key":"B40","doi-asserted-by":"publisher","first-page":"4981","DOI":"10.1038\/s41467-020-18751-8","article-title":"Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism","volume":"11","author":"Killion","year":"2020","journal-title":"Nat Commun"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15216","article-title":"The importance of glucose-dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide","volume":"25","author":"Gasbjerg","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2025.102094","article-title":"Chronic GIPR agonism results in pancreatic islet GIPR functional desensitisation","volume":"92","author":"Davies","year":"2025","journal-title":"Mol Metab"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"key":"B44","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/jdi.12488","article-title":"Searching for the physiological role of glucose-dependent insulinotropic polypeptide","volume":"7","author":"Holst","year":"2016","journal-title":"J Diabetes Invest"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(15)00482-9","article-title":"The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions","volume":"4","author":"Nauck","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2019.170183","article-title":"Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists","volume":"125","author":"Gasbjerg","year":"2020","journal-title":"Peptides"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2019.170230","article-title":"Recent advances of GIP and future horizons","volume":"125","author":"Holst","year":"2020","journal-title":"Peptides"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00577.2005","article-title":"GIP-(3\u201342) does not antagonize insulinotropic effects of GIP at physiological concentrations","volume":"291","author":"Deacon","year":"2006","journal-title":"Am J Physiology-Endocrinology Metab"},{"key":"B49","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/osp4.164","article-title":"Gastric inhibitory polypeptide receptor antagonist, SKL-14959, suppressed body weight gain on diet-induced obesity mice","volume":"4","author":"Nakamura","year":"2018","journal-title":"Obes Sci Pract"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100263","article-title":"GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys","volume":"2","author":"Lu","year":"2021","journal-title":"Cell Rep Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2024.102006","article-title":"AT-7687, a novel GIPR peptide antagonist, combined with a GLP-1 agonist, leads to enhanced weight loss and metabolic improvements in cynomolgus monkeys","volume":"88","author":"Jensen","year":"2024","journal-title":"Mol Metab"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.2337\/db13-1563","article-title":"Chronic reduction of GIP secretion alleviates obesity and insulin resistance under high-fat diet conditions","volume":"63","author":"Nasteska","year":"2014","journal-title":"Diabetes"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/nm727","article-title":"Inhibition of gastric inhibitory polypeptide signaling prevents obesity","volume":"8","author":"Miyawaki","year":"2002","journal-title":"Nat Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aat3392","article-title":"Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models","volume":"10","author":"Killion","year":"2018","journal-title":"Sci Trans Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2019.170174","article-title":"Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease","volume":"125","author":"Heimb\u00fcrger","year":"2020","journal-title":"Peptides"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-37-5-826","article-title":"Stimulation of insulin secretion by gastric inhibitory polypeptide in man.1","volume":"37","author":"Dupre","year":"1973","journal-title":"J Clin Endocrinol Metab"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1139\/y69-020","article-title":"Preparation of highly active enterogastrone","volume":"47","author":"Brown","year":"1969","journal-title":"Can J Physiol Pharmacol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(79)80219-X","article-title":"Release of gastric inhibitory polypeptide (GIP) by intraduodenal acidification in rats and humans and abolishment of the incretin effect of acid by GIP-antiserum in rats","volume":"76","author":"Ebert","year":"1979","journal-title":"Gastroenterology"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/0196-9781(86)90167-1","article-title":"Structural requirements for gastric inhibitory polypeptide (GIP) receptor binding and stimulation of insulin release","volume":"7","author":"Maletti","year":"1986","journal-title":"Peptides"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119060","article-title":"Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat","volume":"98","author":"Tseng","year":"1996","journal-title":"J Clin Invest"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.1999.276.6.E1049","article-title":"Effect of GIP and GLP-1 antagonists on insulin release in the rat","volume":"276","author":"Tseng","year":"1999","journal-title":"Am J Physiology-Endocrinology Metab"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-0115(97)00009-8","article-title":"GIP6\u201330amide contains the high affinity binding region of GIP and is a potent inhibitor of GIP1\u201342action in vitro","volume":"69","author":"Gelling","year":"1997","journal-title":"Regul Peptides"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-4838(01)00181-9","article-title":"Identification of a bioactive domain in the amino-terminus of glucose-dependent insulinotropic polypeptide (GIP)","volume":"1547","author":"Hinke","year":"2001","journal-title":"Biochim Biophys Acta (BBA) - Protein Structure Mol Enzymology"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1023\/A:1022073819618","article-title":"Cyclic AMP production and insulin releasing activity of synthetic fragment peptides of glucose-dependent insulinotropic polypeptide","author":"Gault","year":"2002","journal-title":"Bioscience Rep"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.1750525","article-title":"Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP(3-42), is a GIP receptor antagonist in vivo","volume":"175","author":"Gault","year":"2002","journal-title":"J Endocrinol"},{"key":"B66","doi-asserted-by":"crossref","DOI":"10.1006\/bbrc.2002.6364","article-title":"Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide","volume":"290","author":"Gault","year":"2002","journal-title":"Biochem And Biophys Res Commun"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-002-1028-x","article-title":"Effects of the novel (Pro3)GIP antagonist and exendin(9\u201339)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob\/ob) mice: evidence that GIP is the major physiological incretin","volume":"46","author":"Gault","year":"2003","journal-title":"Diabetologia"},{"key":"B68","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/bph.13323","article-title":"Species-specific action of (Pro3)GIP \u2013 a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors","volume":"173","author":"Sparre-Ulrich","year":"2016","journal-title":"Br J Pharmacol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0003163","article-title":"Vaccination against GIP for the treatment of obesity","volume":"3","author":"Fulurija","year":"2008","journal-title":"PloS One"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2010.12.077","article-title":"Characterization and biological actions of N-terminal truncated forms of glucose-dependent insulinotropic polypeptide","volume":"404","author":"Kerr","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01555.x","article-title":"Biological and functional characteristics of a novel low\u2013molecular weight antagonist of glucose-dependent insulinotropic polypeptide receptor, SKL-14959, in vitro and in vivo","volume":"14","author":"Nakamura","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.426288","article-title":"Structural and pharmacological characterization of novel potent and selective monoclonal antibody antagonists of glucose-dependent insulinotropic polypeptide receptor","volume":"288","author":"Ravn","year":"2013","journal-title":"J Biol Chem"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2014.10.025","article-title":"Antagonism of gastric inhibitory polypeptide (GIP) by palmitoylation of GIP analogues with N- and C-terminal modifications improves obesity and metabolic control in high fat fed mice","volume":"401","author":"Pathak","year":"2015","journal-title":"Mol Cell Endocrinol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1177\/1179551419875453","article-title":"Characterisation of glucose-dependent insulinotropic polypeptide receptor antagonists in rodent pancreatic beta cells and mice","volume":"12","author":"Perry","year":"2019","journal-title":"Clin Med Insights: Endocrinol Diabetes"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-017-4447-4","article-title":"GIP(3-30)NH2 is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study","volume":"61","author":"Gasbjerg","year":"2018","journal-title":"Diabetologia"},{"key":"B76","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.coph.2020.08.011","article-title":"GIP(3-30)NH2 \u2013 a tool for the study of GIP physiology","volume":"55","author":"Lynggaard","year":"2020","journal-title":"Curr Opin Pharmacol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2337\/db20-89-LB","article-title":"89-LB: the effect of GIP on plasma glucose in a setting of prandial insulin overdose and physical activity after meal intake in patients with type 1 diabetes","volume":"69","author":"Hoe","year":"2020","journal-title":"Diabetes"},{"key":"B78","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1530\/EJE-21-0135","article-title":"Effects of endogenous GIP in patients with type 2 diabetes","volume":"185","author":"Stensen","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.2337\/db22-0568","article-title":"The importance of endogenously secreted GLP-1 and GIP for postprandial glucose tolerance and \u03b2-cell function after roux-en-Y gastric bypass and sleeve gastrectomy surgery","volume":"72","author":"Hinds\u00f8","year":"2023","journal-title":"Diabetes"},{"key":"B80","doi-asserted-by":"publisher","first-page":"dgae583","DOI":"10.1210\/clinem\/dgae583","article-title":"GIP receptor antagonism eliminates paradoxical growth hormone secretion in some patients with acromegaly","volume":"10","author":"Jensen","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00125-023-05969-6","article-title":"Extrapancreatic effects of endogenous incretin hormones evaluated using incretin hormone receptor antagonists in totally pancreatectomised patients","volume":"66","author":"Krogh","year":"2023","journal-title":"Diabetologia"},{"key":"B82","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.bcp.2017.02.012","article-title":"GIP(3\u201330)NH2 is a potent competitive antagonist of the GIP receptor and effectively inhibits GIP-mediated insulin, glucagon, and somatostatin release","volume":"131","author":"Sparre-Ulrich","year":"2017","journal-title":"Biochem Pharmacol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00492","article-title":"Increased body weight and fat mass after subchronic GIP receptor antagonist, but not GLP-2 receptor antagonist, administration in rats","volume":"10","author":"Baldassano","year":"2019","journal-title":"Front Endocrinol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s42255-023-00966-w","article-title":"A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings","volume":"6","author":"V\u00e9niant","year":"2024","journal-title":"Nat Metab"},{"key":"B85","unstructured":"Thousand Oaks, Californien\n          Amgen\n          Amgen announces robust weight loss with Maritide in people living with obesity or overweight at 52 weeks in a phase 2 study\n          \n          2024"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2022.101638","article-title":"Discovery of a potent GIPR peptide antagonist that is effective in rodent and human systems","volume":"66","author":"Yang","year":"2022","journal-title":"Mol Metab"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/clinem\/dgz175","article-title":"GIP and GLP-1 receptor antagonism during a meal in healthy individuals","volume":"105","author":"Gasbjerg","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116186","article-title":"Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus","volume":"91","author":"Nauck","year":"1993","journal-title":"J Clin Invest"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-002-0878-6","article-title":"Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients","volume":"45","author":"Vilsb\u00f8ll","year":"2002","journal-title":"Diabetologia"},{"key":"B90","unstructured":"Blocking the effects of endogenous GIP indcreases fasting plasma glucose levels in individuals with obesity\n          \n          \n            \n              Koefoed-Hansen\n              F\n            \n          \n          \n          2024"},{"key":"B91","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/JCI146353","article-title":"GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice","volume":"131","author":"Samms","year":"2021","journal-title":"J Clin Invest"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00471.2015","article-title":"Effects of endogenous GLP-1 and GIP on glucose tolerance after Roux-en-Y gastric bypass surgery","volume":"310","author":"Svane","year":"2016","journal-title":"Am J Physiology-Endocrinology Metab"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00665.2010","article-title":"The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes","volume":"300","author":"Lund","year":"2011","journal-title":"Am J Physiology-Endocrinology Metab"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1210\/endo.139.9.6288","article-title":"Functional GIP receptors are present on adipocytes","volume":"139","author":"Yip","year":"1998","journal-title":"Endocrinology"},{"key":"B95","first-page":"11","article-title":"Obesity is associated with increased post-prandial GIP levels which are not reduced by dietary restriction and weight loss","volume":"15","author":"Jones","year":"1989","journal-title":"Diabete Metab"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00351.2013","article-title":"Chronic high-fat feeding increases GIP and GLP-1 secretion without altering body weight","volume":"309","author":"Wang","year":"2015","journal-title":"Am J Physiology-Gastrointestinal Liver Physiol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41588-017-0011-x","article-title":"Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity","volume":"50","author":"Meidtner","year":"2018","journal-title":"Nat Genet"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf8683","article-title":"Sequencing of 640,000 exomes identifies GPR75 variants associated with protection from obesity","volume":"373","author":"Akbari","year":"2021","journal-title":"Science"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.749607","article-title":"Loss of function glucose-dependent insulinotropic polypeptide receptor variants are associated with alterations in BMI, bone strength and cardiovascular outcomes","volume":"9","author":"Kizilkaya","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bone.2019.115079","article-title":"GIP\u2019s effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3\u201330)NH2","volume":"130","author":"Gasbjerg","year":"2020","journal-title":"Bone"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-3766","article-title":"A functional amino acid substitution in the glucose-dependent insulinotropic polypeptide receptor (GIPR) gene is associated with lower bone mineral density and increased fracture risk","volume":"99","author":"Torekov","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad734","article-title":"Obesity variants in the GIPR gene are not associated with risk of fracture or bone mineral density","volume":"109","author":"Styrkarsdottir","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1038\/ng.686","article-title":"Association analyses of 249,796 individuals reveal eighteen new loci associated with body mass index","volume":"42","author":"Speliotes","year":"2010","journal-title":"Nat Genet"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2024.04.016","article-title":"Antagonizing GIPR adds fire to the GLP-1R flame","volume":"35","author":"Novikoff","year":"2024","journal-title":"Trends Endocrinol Metab"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-022-00783-3","article-title":"Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1","volume":"19","author":"Hammoud","year":"2023","journal-title":"Nat Rev Endocrinol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15875","article-title":"A long-acting glucose-dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon-like peptide-1 receptor agonist therapy","volume":"26","author":"Knop","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"B107","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/0196-9781(94)90016-7","article-title":"Gastric inhibitory polypeptide (GIP) binding sites in rat brain","volume":"15","author":"Kaplan","year":"1994","journal-title":"Peptides"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2010.513381","article-title":"Therapeutic potential of the original incretin hormone glucose-dependent insulinotropic polypeptide: diabetes, obesity, osteoporosis and Alzheimer\u2019s disease","volume":"19","author":"Irwin","year":"2010","journal-title":"Expert Opin Investigational Drugs"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2010.10.059","article-title":"Prolonged GIP receptor activation improves cognitive function, hippocampal synaptic plasticity and glucose homeostasis in high-fat fed mice","volume":"650","author":"Porter","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4920-04.2005","article-title":"Glucose-dependent insulinotropic polypeptide is expressed in adult hippocampus and induces progenitor cell proliferation","volume":"25","author":"Nyberg","year":"2005","journal-title":"J Neurosci"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1152\/jn.00866.2010","article-title":"Glucose-dependent insulinotropic polypeptide receptor knockout mice are impaired in learning, synaptic plasticity, and neurogenesis","volume":"105","author":"Faivre","year":"2011","journal-title":"J Neurophysiol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1002\/mnfr.200700048","article-title":"Association analyses of GIP and GIPR polymorphisms with traits of the metabolic syndrome","volume":"51","author":"Nitz","year":"2007","journal-title":"Mol Nutr Food Res"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.2337\/db21-0103","article-title":"Genetically predicted glucose-dependent insulinotropic polypeptide (GIP) levels and cardiovascular disease risk are driven by distinct causal variants in the GIPR region","volume":"70","author":"Bowker","year":"2021","journal-title":"Diabetes"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2017.11.021","article-title":"Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents","volume":"100","author":"Gasbjerg","year":"2018","journal-title":"Peptides"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14507","article-title":"Exendin(9-39) NH 2 : Recommendations for clinical use based on a systematic literature review","volume":"23","author":"Gasbjerg","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"B116","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"New Engl J Med"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13979","article-title":"Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens","volume":"22","author":"Frias","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"New Engl J Med"},{"key":"B119","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.cmet.2019.07.013","article-title":"Glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus regulate food intake","volume":"30","author":"Adriaenssens","year":"2019","journal-title":"Cell Metab"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.140532","article-title":"Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist","volume":"5","author":"Willard","year":"2020","journal-title":"JCI Insight"},{"key":"B122","doi-asserted-by":"publisher","first-page":"bph.16478","DOI":"10.1111\/bph.16478","article-title":"Altered desensitization and internalization patterns of rodent versus human glucose-dependent insulinotropic polypeptide (GIP) receptors. An important drug discovery challenge","volume":"181","author":"Gasbjerg","year":"2024","journal-title":"Br J Pharmacol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.06.003","article-title":"Transforming obesity: The advancement of multi-receptor drugs","volume":"187","author":"Kusminski","year":"2024","journal-title":"Cell"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2024.171212","article-title":"GIP-derived GIP receptor antagonists \u2013 a review of their role in GIP receptor pharmacology","volume":"177","author":"Rosenkilde","year":"2024","journal-title":"Peptides"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1570603\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:14:24Z","timestamp":1747786464000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1570603\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":124,"alternative-id":["10.3389\/fendo.2025.1570603"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1570603","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,21]]},"article-number":"1570603"}}